Hyloris Announces the final Conversion Price of its EUR 1 Million Convertible Bonds

Liège, Belgium – 2 November 2026 – 09:30 PM CET – Regulated information – Hyloris Pharmaceuticals SA ("Hyloris") (Euronext Brussels: HYL) today announces, with reference to its press release of 28 October 2026, the conversion price of its EUR 1,000,000 convertible bonds.

The convertible bonds will be convertible into ordinary shares of Hyloris at a conversion price of EUR 4,8653 (rounded) which represents a 33.33% premium to the reference price of EUR 3,6491 (rounded) being the volume-weighted average price (VWAP) of the Hyloris share over the three consecutive trading days starting on 29 October 2026.

For more information on the convertible bonds, please refer to the press release of 28 October 2026.

The effective subscription and issuance of the convertible bonds will take place at Hyloris' first request, and at the latest on the fifteenth day following the publication of Hyloris' 2026 annual financial report.

About Hyloris Pharmaceuticals

Hyloris is a specialty pharma group focused on reinventing and optimizing existing medications through reformulation and repurposing to address important healthcare needs and deliver meaningful improvements for patients, healthcare professionals, and payers. The Company's development strategy primarily focuses on leveraging established regulatory pathways, such as the FDA's 505(b)(2) pathway in the U.S., or equivalent regulatory frameworks in other regions, which are specifically designed for pharmaceuticals for which safety and efficacy of the molecule have already been established. This approach can reduce the clinical and regulatory burden required for market entry, and significantly shorten development timelines, leading to reduced costs and risks. Hyloris has a broad development portfolio including more than 25 value-added medicines of which two are currently in early stages of commercialization in collaboration with commercial partners: Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid post-operative pain treatment. In addition to its core strategic focus, the Company has two high-barrier generic products approved and commercialized in the U.S.: Podofilox Gel and Tranexamic Acid RTU. Beyond its announced portfolio, Hyloris has initiated several additional internal early-stage development activities, bringing the total pipeline to more than 30 products and product candidates, and continues to evaluate further product opportunities to support future growth. ***Where others stop, Hyloris starts and adds value through Reinventing Existing Medicines for unmet patient needs worldwide***. Hyloris is based in Liège, Belgium and since 2020 listed on Euronext Brussels (XBR: HYL) with about 54 people across 13 nationalities, targeting time-to-market of 7 years at an average cost of EUR 7 million per product (non-inflation adjusted).

For more information, visit www.hyloris.com and follow-us on LinkedIn.

Contacts Hyloris Pharmaceuticals :

Ann De Jaeger, CLO
legal representative of Impact WITH Empathy BV
Ann.dejaeger@hyloris.com
32 (0)475 20 13 44 - 32 (0)4 346 02 07

Stijn Van Rompay, CEO
legal representative of SVR Management BV
stijn.vanrompay@hyloris.com
32 (0)4 346 02 07

Christophe Maréchal, CFO
legal representative of CMM&C srl
Christophe.Marechal@hyloris.com
32 (0)4 346 02 07

Disclaimer and forward-looking statements

Hyloris means “high yield, lower risk”, which relates to the 505(b)(2) regulatory pathway for product approval on which the Company focuses, but in no way relates or applies to an investment in the Shares. Certain statements in this press release are “forward-looking statements.” These forward-looking statements can be identified using forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. These statements relate to future events or the Company’s future financial performance and involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control, that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, and no securities may be offered or sold in any jurisdiction in which such offer, solicitation or sale would be unlawful.